Retrospective Study Looking at Cinacalcet in the Management of Hyperparathyroidism after Kidney Transplantation
Autor: | Vincent Pichette, Michel Vallée, Sarah Bezzaoucha, Robert Bell, Hugues Bouchard, Anne Boucher, Lynne Senécal, Denis Ouimet, Jean-Philippe Lafrance, Duy Tran, Habib Mawad, Suzon Collette |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2017 |
Předmět: |
Hyperparathyroidism
Pediatrics medicine.medical_specialty Cinacalcet Article Subject business.industry 030232 urology & nephrology lcsh:Surgery Retrospective cohort study lcsh:RD1-811 030230 surgery medicine.disease Kidney transplant Surgery Transplantation 03 medical and health sciences 0302 clinical medicine Chart review Clinical Study medicine Effective treatment business Kidney transplantation medicine.drug |
Zdroj: | Journal of Transplantation, Vol 2017 (2017) Journal of Transplantation |
ISSN: | 2090-0015 2090-0007 |
Popis: | Objectives.The primary objective of this study is to evaluate the use of cinacalcet in the management of hyperparathyroidism in kidney transplant recipients. The secondary objective is to identify baseline factors that predict cinacalcet use after transplantation.Methods.In this single-center retrospective study, we conducted a chart review of all patients having been transplanted from 2003 to 2012 and having received cinacalcet up to kidney transplantation and/or thereafter.Results.Twenty-seven patients were included with a mean follow-up of2.9±2.4years. Twenty-one were already taking cinacalcet at the time of transplantation. Cinacalcet was stopped within the first month in 12 of these patients of which 7 had to restart therapy. The main reason for restarting cinacalcet was hypercalcemia. Length of treatment was23±26months. There were only 3 cases of mild hypocalcemia. There was no statistically significant association between baseline factors and cinacalcet status a year later.Conclusions.Discontinuing cinacalcet within the first month of kidney transplantation often leads to hypercalcemia. Cinacalcet appears to be an effective treatment of hypercalcemic hyperparathyroidism in kidney transplant recipients. Further studies are needed to evaluate safety and long-term benefits. |
Databáze: | OpenAIRE |
Externí odkaz: |